Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

biliary tract cancer News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A new study evaluates minimal residual disease (MRD) and longitudinal monitoring of biliary tract cancer using a customized circulating tumor DNA (ctDNA) panel. This research could enhance post-surgery monitoring strategies for patients with this challenging cancer type.

Compass Therapeutics will proceed with its FDA application for a drug targeting advanced biliary tract cancer, despite the FDA's request for a new clinical study. The company emphasizes the urgent need for treatment options in this patient population.

A new study explores the molecular subtyping of biliary tract neuroendocrine carcinomas, highlighting key clinicopathological features and their prognostic implications. This research could inform future therapeutic strategies for this rare cancer type.

Recent deep molecular profiling of biliary tract cancer reveals new biological mechanisms and potential therapeutic targets. This research could pave the way for innovative treatment strategies in a challenging cancer type.

A recent study analyzes the global research landscape and trends in immunotherapy for biliary tract cancers. The findings highlight the increasing focus on innovative treatment approaches in this challenging area.

Not rare diseases news,news about your rare disease.

Earlier

A new study evaluates minimal residual disease (MRD) and longitudinal monitoring of biliary tract cancer using a customized circulating tumor DNA (ctDNA) panel. This research could enhance post-surgery monitoring strategies for patients with this challenging cancer type.

Compass Therapeutics will proceed with its FDA application for a drug targeting advanced biliary tract cancer, despite the FDA's request for a new clinical study. The company emphasizes the urgent need for treatment options in this patient population.

A new study explores the molecular subtyping of biliary tract neuroendocrine carcinomas, highlighting key clinicopathological features and their prognostic implications. This research could inform future therapeutic strategies for this rare cancer type.

Recent deep molecular profiling of biliary tract cancer reveals new biological mechanisms and potential therapeutic targets. This research could pave the way for innovative treatment strategies in a challenging cancer type.

A recent study analyzes the global research landscape and trends in immunotherapy for biliary tract cancers. The findings highlight the increasing focus on innovative treatment approaches in this challenging area.

Not rare diseases news,
news about your rare disease.